Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA
- 1 December 2006
- journal article
- case report
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
- Vol. 100 (12) , 1183-1186
Abstract
A male patient with psoriatic arthritis and visceral Leishmania infantum infection was treated with oral miltefosine 50 mg three times a day for 4 weeks at the Academic Medical Center, Amsterdam, The Netherlands. Miltefosine plasma concentrations were measured with liquid chromatography/mass spectrometry. The parasite load was followed by quantitative nucleic acid sequence-based amplification (QT-NASBA) assay in blood. Miltefosine elicited a prompt therapeutic effect. After an initial worsening of symptoms and an increase of QT-NASBA values during the first week, recovery was rapidly achieved. QT-NASBA values declined exponentially and were negative after 6 weeks. Miltefosine plasma concentrations continued to accumulate during the 4 weeks of treatment. The terminal elimination half-life was 14.8 days.Keywords
This publication has 5 references indexed in Scilit:
- Quantitative Nucleic Acid Sequence-Based Assay as a New Molecular Tool for Detection and Quantification of Leishmania Parasites in Skin Biopsy SamplesJournal of Clinical Microbiology, 2005
- Miltefosine to treat leishmaniasisExpert Opinion on Pharmacotherapy, 2005
- Oral Miltefosine for Indian Visceral LeishmaniasisNew England Journal of Medicine, 2002
- Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumoursEuropean Journal of Cancer, 2002
- Treatment of American Cutaneous Leishmaniasis with Miltefosine, an Oral AgentClinical Infectious Diseases, 2001